These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31279576)

  • 1. Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations.
    Solomon GM; Nichols DP
    J Cyst Fibros; 2019 Sep; 18(5):579-580. PubMed ID: 31279576
    [No Abstract]   [Full Text] [Related]  

  • 2. Important steps in the journey to highly effective CFTR modulator access for people with CF.
    VanDevanter DR; Mayer-Hamblett N
    J Cyst Fibros; 2019 Sep; 18(5):577-578. PubMed ID: 31500809
    [No Abstract]   [Full Text] [Related]  

  • 3. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.
    Davies JC; Drevinek P; Elborn JS; Kerem E; Lee T; ; Amaral MD; de Boeck K; Davies JC; Drevinek P; Elborn JS; Kerem E; Lee T
    J Cyst Fibros; 2019 Sep; 18(5):677-684. PubMed ID: 31303382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations.
    Amaral MD; de Boeck K;
    J Cyst Fibros; 2019 Sep; 18(5):685-692. PubMed ID: 31326274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At the forefront of cystic fibrosis Basic Science research: 16th ECFS Basic Science Conference.
    Taggart CC; Weldon S; Mall MA
    J Cyst Fibros; 2020 Mar; 19(2):169-170. PubMed ID: 32063486
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world evidence in cystic fibrosis modulator development: Establishing a path forward.
    Magaret A; Warden M; Simon N; Heltshe S; Mayer-Hamblett N
    J Cyst Fibros; 2020 May; 19(3):e11-e12. PubMed ID: 32291159
    [No Abstract]   [Full Text] [Related]  

  • 7. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
    Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
    Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CFTR pharmacology.
    Zegarra-Moran O; Galietta LJ
    Cell Mol Life Sci; 2017 Jan; 74(1):117-128. PubMed ID: 27704174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R560S: A class II CFTR mutation that is not rescued by current modulators.
    Awatade NT; Ramalho S; Silva IAL; Felício V; Botelho HM; de Poel E; Vonk A; Beekman JM; Farinha CM; Amaral MD
    J Cyst Fibros; 2019 Mar; 18(2):182-189. PubMed ID: 30030066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.
    Donaldson SH; Solomon GM; Zeitlin PL; Flume PA; Casey A; McCoy K; Zemanick ET; Mandagere A; Troha JM; Shoemaker SA; Chmiel JF; Taylor-Cousar JL
    J Cyst Fibros; 2017 May; 16(3):371-379. PubMed ID: 28209466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
    Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
    Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reshma Kewalramani.
    Mullard A
    Nat Rev Drug Discov; 2019 Nov; 18(12):896-897. PubMed ID: 31780855
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
    Kym PR; Wang X; Pizzonero M; Van der Plas SE
    Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability.
    Ferrera L; Baroni D; Moran O
    J Cyst Fibros; 2019 Sep; 18(5):602-605. PubMed ID: 30738802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pluripotent Stem Cell Platforms for Drug Discovery.
    Chen KG; Mallon BS; Park K; Robey PG; McKay RDG; Gottesman MM; Zheng W
    Trends Mol Med; 2018 Sep; 24(9):805-820. PubMed ID: 30006147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.